To advance scientific progress with any cell type, a basic level of knowledge needs to be acquired, including protocols for cell isolation, growth, expansion, differentiation, and more. It requires that characteristics of the cells be observed to determine how they are affected by environmental variation. To date, a significant amount has been learned about mesenchymal stem cells, as 30,697 scientific articles have been published about the cell type.[1] Of those, more than half (17,998) have been published within the last five years.[2] [Read more…]
STEMCELL Technologies Partners with IMBA to Commercialize Brain Organoids
(‘Mini Brains’) for Researchers
Major Announcements in Stem Cell Sector – Cynata, Gamida Cell, Pluristem, Universal Cells, and More
Suffice it to say, it has been a banner week in the world of stem cells. In this rapidly-changing market environment, it can be difficult to keep up with current events. To help you out, we’ve released new content on stem cell markets that we are excited to share with you. Let me know what you think! [Read more…]
Pluristem Fortifies IP Position and Partnering Potential in Japan with Two Key Cell Therapy Patents
In major news released today, Pluristem Therapeutics announced that it had been granted two key cell therapy patents in Japan. Pluristem Therapeutics is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.
Therefore, the patents pertain to the three-dimensional growth of placental and fat cells and the use of placental cells grown with 3D technology:
- Patent No. 5733894, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy
- Patent No. 5766041, titled “Pharmaceutical Composition for Enhancing Subject Hematopoietic System”
To learn more about the company, see our recent interview Dr. Racheli Ofir, VP Research & Intellectual Property for Pluristem Therapeutics. Or, read the full press release below, printed with permission from Dr. Ofir. [Read more…]
European Bank for iPS Cells Launches Cells for Disease Modelling and Preclinical Research
Recently the European Bank for induced pluripotent Stem Cells (EBiSC) announced the launch of its on-line catalogue of iPSCs for use in disease modeling and pre-clinical research. The cell lines were created and deposited by EBiSC partner labs and a broad range of external organisations.
Upcoming efforts will introduce to the bank a large number of Parkinson’s and Alzheimer’s Disease lines, as well as lines for diabetes, cardiovascular research, muscular dystrophies, neuropathic pain, and more. These new lines will be produced through external collaborations, as well as cell line creation within the EBiSC.
Specifically, EBiSC announced: [Read more…]
- « Previous Page
- 1
- …
- 165
- 166
- 167
- 168
- 169
- …
- 200
- Next Page »